Alinity i

The new assay quantitatively determines the level of Methotrexate in human serum and plasma using chemiluminescent microparticle immunoassay (CMIA) technology with flexible assay protocols. The new ARCHITECT Methotrexate assay (LN 2P49) will replace the current TDx/TDxFLx Methotrexate assay (LN7A12).